is tirzepatide on the fda shortage list says this weight loss drug over, but patients worry about cost and availability FDA says shortage of GLP-1

Supports immune functions

It could be speculated that this increased discontinuation rate vs all comparators, including GLP-1 RAs, may be possibly attributed to the severity of gastrointestinal adverse events experienced with tirzepatide 15 mg, considering that the incidence of gastrointestinal adverse events was similar between tirzepatide and GLP-1 RAs

Irie N, Takada Y, Watanabe Y, Matsuzaki Y, Naruse C, Asano M, et al

Journal of [...] Disease

Additionally, two small studies in participants presenting with antiretroviral-induced neuropathy found significant reduction in subjects' mean pain intensity with oral ALCAR (1-3 g/day) for 4 to 24 weeks, but no effect on objective neurophysiological parameters was found (82, 83)

A large-scale study involving over 145,000 participants treated with GLP-1 agonists found no significant increase in thyroid cancer risk compared to those treated with other diabetes medications